List of Excipients in Branded Drug GEMFIBROZIL

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Greenstone LLC	GEMFIBROZIL	gemfibrozil	59762-0737	CALCIUM STEARATE
Greenstone LLC	GEMFIBROZIL	gemfibrozil	59762-0737	CANDELILLA WAX
Greenstone LLC	GEMFIBROZIL	gemfibrozil	59762-0737	CELLULOSE, MICROCRYSTALLINE

Generic Drugs Containing GEMFIBROZIL

Company	Ingredient	NDC	Excipient
West-ward Pharmaceutical Corp	gemfibrozil	0143-9130	CALCIUM STEARATE
West-ward Pharmaceutical Corp	gemfibrozil	0143-9130	CELLULOSE, MICROCRYSTALLINE
West-ward Pharmaceutical Corp	gemfibrozil	0143-9130	CROSCARMELLOSE SODIUM

What are the Most Frequently-Used Excipients in GEMFIBROZIL?

# Of NDCs	Excipient
5	BUTYL ALCOHOL
79	CALCIUM STEARATE
8	CARNAUBA WAX

Gemfibrozil Excipient Strategy and Commercial Opportunities

Last updated: August 9, 2026

Gemfibrozil is a mature, orally administered fibrate with limited patent protection and intense generic competition. The commercial opportunity is not a conventional new-drug exclusivity play. It lies in improving manufacturability, tablet robustness, dissolution consistency, swallowing convenience, supply reliability, and potentially drug-interaction management through formulation design. The principal technical constraint is gemfibrozil’s low aqueous solubility and clinically important administration requirement before meals.[1][2]

What is the commercial status of gemfibrozil?

Gemfibrozil is a small-molecule lipid-regulating drug used primarily to reduce triglycerides and raise high-density lipoprotein cholesterol in selected patients. The reference product, Lopid, was marketed as 600 mg tablets and 300 mg capsules. U.S. generic products are primarily immediate-release oral tablets, with strengths and excipient systems varying by manufacturer.[1][3]

Attribute	Gemfibrozil
Active ingredient	Gemfibrozil
Therapeutic class	Fibric acid derivative
Primary dosage forms	Immediate-release tablets; historical capsules
Common strength	600 mg
Historical dosing	600 mg twice daily, approximately 30 minutes before morning and evening meals
Route	Oral
Solubility issue	Low aqueous solubility
Key pharmacokinetic issue	Food effect and drug-drug interaction liability
Main U.S. market	Generic prescription market
Biosimilar exposure	None; gemfibrozil is a small molecule
Primary commercial barrier	Low price and established generic substitution

Gemfibrozil is not a biologic and therefore has no biosimilar pathway. Competition occurs through abbreviated new drug applications, therapeutic substitution, distributor contracts, and pharmacy purchasing rather than biosimilar interchangeability.

What patents protect gemfibrozil?

The original composition-of-matter and product patents for gemfibrozil are long expired. Gemfibrozil has been commercially available for decades, and standard immediate-release products do not depend on a live core patent estate for market access.

Patent category	Current commercial relevance
Gemfibrozil molecule	Expired
Original oral product claims	Expired or commercially immaterial
Conventional immediate-release tablet	Generally unprotected by an active pioneer patent
New formulation claims	Potentially available if technically differentiated and non-obvious
Method-of-use claims	Limited opportunity because the main lipid indications are established
Manufacturing-process claims	Possible, but value depends on process advantage and enforceability
Device or packaging claims	Possible for adherence or stability products, but narrow

A new formulation could receive patent protection if it produces a defensible technical effect, such as materially improved dissolution, reduced food sensitivity, a new release profile, or a clinically meaningful reduction in dosing frequency. Simply replacing lactose with mannitol, changing a disintegrant, or selecting a standard coating system would generally provide weak patent differentiation unless supported by unexpected performance data.

When does gemfibrozil lose exclusivity?

Gemfibrozil’s practical market exclusivity ended long ago. Generic competition has displaced the branded product in routine U.S. prescribing, and the market is governed by abbreviated approval pathways rather than pending pioneer exclusivity.

The relevant exclusivity profile is:

Exclusivity type	Assessment
New chemical entity exclusivity	Expired
Orphan-drug exclusivity	Not the basis of the product’s market
Pediatric exclusivity	No material current barrier
Reference-product exclusivity	Expired
Active core patent exclusivity	Not commercially relevant
Generic entry	Established
180-day Paragraph IV exclusivity	Historical issue only, not a current barrier to the mature market

A company developing a new gemfibrozil product should assume that the active ingredient, conventional dosage form, and established indications are open to generic competition.

What excipients are used in gemfibrozil tablets?

Gemfibrozil excipients are manufacturer-specific. Public U.S. labels identify several recurring excipient classes, including fillers, binders, disintegrants, lubricants, glidants, surfactants, and film-coating materials.[3][4]

Representative excipient functions include:

Excipient class	Examples used in oral solid-dose systems	Role in gemfibrozil formulation
Diluent	Microcrystalline cellulose, lactose, starch	Provides tablet mass and compressibility
Binder	Povidone, pregelatinized starch, hypromellose	Improves granule and tablet cohesion
Disintegrant	Croscarmellose sodium, sodium starch glycolate	Promotes tablet breakup after administration
Lubricant	Magnesium stearate	Reduces ejection force and tooling adhesion
Glidant	Colloidal silicon dioxide, talc	Improves powder flow
Surfactant	Sodium lauryl sulfate, polysorbate systems	Supports wetting of the poorly soluble drug
Coating polymer	Hypromellose	Provides film coating and handling protection
Opacifier or pigment	Titanium dioxide, iron oxides	Product identification and appearance
Solubilizing or wetting aid	Selected surfactant or polymer systems	May improve dissolution consistency

Excipient selection should be driven by dissolution behavior rather than tablet appearance. Gemfibrozil has low water solubility, making wetting, particle size, granulation method, and disintegration more important than simply increasing tablet hardness.

How should an excipient strategy address gemfibrozil’s solubility?

The preferred strategy is an immediate-release formulation that improves wetting and dispersion without creating an unnecessarily complex product. The development target should be rapid and reproducible dissolution under pharmacopeial and discriminatory test conditions.

Direct-compression strategy

Direct compression can reduce manufacturing cost and processing time. It is suitable where the active pharmaceutical ingredient has acceptable flow, compressibility, and particle-size control.

A practical direct-compression system may combine:

• Microcrystalline cellulose as the primary diluent.
• Croscarmellose sodium as the principal superdisintegrant.
• Colloidal silicon dioxide for flow enhancement.
• Magnesium stearate at a controlled concentration.
• A low level of surfactant where dissolution testing supports its use.

The main risk is segregation if the active ingredient and excipients have materially different particle-size distributions or densities. Blend uniformity and dissolution can deteriorate even when assay results remain acceptable.

Wet-granulation strategy

Wet granulation is more suitable when the active ingredient has poor flow or when higher tablet strength is needed. Povidone or pregelatinized starch can improve granule integrity. The process must control granule moisture and endpoint because over-granulation may delay disintegration and dissolution.

Wet granulation also creates a larger process-development burden. It may be justified for high-volume products where lower tablet-failure rates and improved compression performance offset the additional manufacturing steps.

Surfactant-assisted strategy

A surfactant can improve wetting of gemfibrozil particles. Sodium lauryl sulfate is a common technical candidate, but its use requires careful control of concentration, taste contribution, gastrointestinal tolerability, and regulatory precedent.

A surfactant should not be treated as a universal dissolution solution. Excessive levels can alter granulation behavior, tablet strength, disintegration, and impurity profiles. A formulation with lower surfactant loading and a controlled particle-size distribution may be commercially preferable to a heavily surfactant-dependent design.

Particle engineering

Particle-size reduction, micronization, or controlled agglomeration may improve dissolution. These approaches can create stronger patent positions than routine excipient substitution if the product demonstrates:

• A defined particle-size distribution.
• Improved dissolution across pH conditions.
• Reduced batch-to-batch variability.
• Equivalent or improved exposure relative to the reference product.
• Stable performance after compression and storage.

Particle engineering also creates manufacturing and containment requirements. Fine powders can increase dusting, electrostatic charging, and operator-exposure controls.

What formulations are protected by new gemfibrozil patents?

Potentially protectable formulation concepts include:

1. Rapid-dissolution immediate-release tablets using a defined particle-size range and surfactant system.
2. Taste-masked oral granules or orally disintegrating tablets.
3. Modified-release products that reduce twice-daily dosing.
4. Fixed-dose combinations with another lipid-lowering agent.
5. Multiparticulate systems that reduce food-dependent absorption.
6. Solid dispersions or lipid-based systems that improve apparent solubility.
7. Abuse-deterrent or tamper-resistant packaging, although this has limited relevance for gemfibrozil.
8. Manufacturing processes that produce a narrow dissolution profile at lower cost.

The strongest patent claims would link composition variables to measurable product performance. Claims based only on a list of conventional excipients are likely to face obviousness challenges, especially for a well-known generic drug.

What FDA regulatory issues affect gemfibrozil reformulation?

A conventional generic immediate-release tablet would generally proceed through an ANDA if it matches the reference product in dosage form, strength, route, and relevant performance requirements. A materially different release profile, dosage form, or dosing regimen could require a different regulatory pathway, potentially including a 505(b)(2) application.[5]

Key regulatory considerations include:

Development issue	Regulatory impact
Immediate-release tablet	Potential ANDA pathway if sameness and bioequivalence requirements are met
New strength	May require additional bioequivalence and safety justification
Extended-release product	Likely requires a separate clinical and pharmacokinetic development program
Orally disintegrating tablet	May require evidence supporting dose delivery and bioequivalence
New excipient or novel level	Requires safety justification and precedent assessment
Food-effect reduction	Requires pharmacokinetic evidence
Fixed-dose combination	Requires combination rationale and component exposure data
Narrow therapeutic claim	Must align with approved labeling
Drug interaction claim	Requires robust clinical pharmacology evidence

Gemfibrozil has important interaction restrictions. The FDA label warns against coadministration with simvastatin because of the risk of severe muscle toxicity and rhabdomyolysis. Gemfibrozil also inhibits CYP2C8 and can interact with other medicines, including repaglinide.[1] A formulation that increases exposure could worsen the interaction profile. A formulation that lowers peak concentration without reducing lipid-lowering efficacy could have commercial value, but it would require clinical evidence.

What is the Orange Book status of gemfibrozil?

The Orange Book relevance for gemfibrozil is primarily therapeutic-equivalence and reference-product identification rather than active patent certification. Gemfibrozil generic tablets have been marketed through the ANDA system for many years. A current product-specific review should distinguish:

• Approved reference listed drug status.
• Therapeutic-equivalence ratings for individual ANDA products.
• Any patents or exclusivity associated with a particular current listing.
• Discontinued versus active product presentations.
• Strength-specific approval status.

Because the market contains multiple generic presentations, an applicant should not assume that all historical strengths, capsule products, and tablet products have identical regulatory status. The practical commercial question is whether the proposed product can obtain an AB rating against the relevant reference product and compete on contracted pricing.

Which companies are challenging the gemfibrozil market?

The market is challenged by established generic manufacturers and private-label suppliers rather than by a single branded challenger. Competition is likely to include companies that manufacture or source standard oral solid-dose products for retail, institutional, and mail-order channels.

The main competitive factors are:

• Lowest reliable acquisition cost.
• Therapeutic-equivalence rating.
• Supply continuity.
• Packaging flexibility.
• Ability to support wholesaler and pharmacy contracts.
• Stable dissolution and low complaint rates.
• Availability of 300 mg and 600 mg presentations.
• Manufacturing capacity in the United States or approved foreign facilities.

A new entrant should expect price competition from products that already satisfy routine prescribing needs. A differentiated formulation must solve a specific problem, such as swallowing difficulty, poor adherence, food-related variability, or supply disruption.

What commercial opportunities exist for gemfibrozil excipient innovation?

Low-cost supply and second-source manufacturing

The most realistic opportunity is a robust, low-cost immediate-release tablet with simplified excipient procurement. A formulation that tolerates moderate raw-material variability and maintains dissolution after scale-up can support contract manufacturing and private-label supply.

Patient-centric dosage forms

Potentially differentiated products include:

• Smaller high-dose tablets.
• Orally disintegrating tablets.
• Sprinkle capsules.
• Taste-masked granules.
• Unit-dose packaging for twice-daily administration.

The 600 mg dose creates a physical tablet-size challenge. A smaller tablet with equivalent performance could have value in patients with dysphagia, although the commercial market may be limited unless the product secures favorable reimbursement.

Fixed-dose combinations

A gemfibrozil combination with another lipid agent could improve adherence, but the pharmacology is restrictive. Gemfibrozil’s interaction profile creates a substantial barrier to combinations with several statins. A combination product would require a clear clinical rationale and careful interaction evaluation.

Modified-release products

Once-daily dosing is commercially attractive, but an extended-release formulation would require more than an excipient change. Development would involve pharmacokinetic modeling, dose proportionality, food-effect assessment, and likely clinical efficacy support. The opportunity is technically credible but economically difficult in a low-price generic market.

International markets

Markets with limited generic availability, inconsistent supply, or high demand for triglyceride-lowering therapy may offer better margins than the U.S. market. Geographic strategy should focus on:

• Local registration requirements.
• Reference-product availability.
• Import and serialization rules.
• Local excipient acceptance.
• Stability under climatic zone conditions.
• Tender versus retail distribution.
• Patent status in the target country.

A formulation developed for hot and humid climates could create a modest commercial advantage if it maintains dissolution and mechanical integrity without premium packaging.

What manufacturing and IP barriers exist?

The principal manufacturing barriers are process control and commercial scale rather than active-ingredient patent risk.

Important controls include:

• Active particle-size distribution.
• Blend uniformity.
• Lubrication time.
• Granulation endpoint.
• Tablet hardness and friability.
• Disintegration time.
• Dissolution across pH conditions.
• Moisture uptake.
• Coating uniformity.
• Stability of the selected surfactant system.

An IP strategy should focus on a narrow, evidence-supported claim set. The most defensible candidates are process or formulation claims tied to a demonstrated technical benefit. Broad claims covering gemfibrozil with common fillers, binders, or disintegrants would likely have limited blocking power.

What generic entry risks exist for a new gemfibrozil product?

Generic entry risk is high because the active ingredient is old, the clinical indications are established, and the product is available in conventional oral solid forms. A new entrant faces four principal risks:

1. Price erosion from established ANDA sponsors.
2. Limited physician demand for a reformulated version.
3. Regulatory reclassification if the product departs materially from the reference dosage form.
4. Weak patent protection for routine excipient changes.

A differentiated product should therefore combine formulation IP with a commercial access strategy, such as a manufacturing license, pharmacy benefit positioning, hospital contract, or regional distribution agreement.

What patent litigation and settlement agreements affect gemfibrozil?

Gemfibrozil is a legacy generic product without a major current branded patent dispute shaping market entry. Historical Paragraph IV activity may have occurred during the original genericization period, but it is not the central commercial issue for present-day development.

No biosimilar litigation applies. A new applicant should focus on ordinary ANDA patent certification, product-specific Orange Book review, and freedom-to-operate analysis for any newly selected excipient system, release technology, or combination product.

How does gemfibrozil compare with competing lipid-lowering drugs?

Gemfibrozil competes with fenofibrate, statins, omega-3 products, and newer triglyceride-lowering therapies.

Product class	Relative advantage	Commercial implication
Gemfibrozil	Low acquisition cost; established fibrate	Strong generic price competition
Fenofibrate	Broader once-daily formulation options and fewer statin interaction concerns in common practice	More attractive for combination lipid management
Statins	Strong cardiovascular-outcome evidence and broad guideline use	Limits gemfibrozil demand in mixed dyslipidemia
Prescription omega-3 products	Targeted triglyceride reduction in selected patients	Higher-cost niche market
Newer triglyceride agents	Potentially stronger efficacy or specialized indications	May reduce future demand for older fibrates

Gemfibrozil’s strongest commercial position is as a low-cost generic for selected patients requiring fibrate therapy. Its weakest position is in routine mixed dyslipidemia where statins or fenofibrate may be preferred.

Key Takeaways

• Gemfibrozil has no meaningful remaining core patent exclusivity in the conventional U.S. generic market.
• Excipient innovation should target dissolution, wetting, tablet size, manufacturing robustness, and food-effect management.
• Routine substitution of common excipients is unlikely to produce strong patent protection.
• A 600 mg immediate-release tablet remains the most commercially practical development target.
• Orally disintegrating, smaller, sprinkle, or once-daily products offer differentiation but require regulatory and economic justification.
• The FDA interaction warnings, especially with simvastatin and CYP2C8 substrates, constrain exposure-enhancing formulations and fixed-dose combinations.[1]
• Generic price competition is the principal market risk.
• A viable investment case requires a measurable formulation benefit, an efficient regulatory pathway, and a distribution advantage.

FAQs

Can gemfibrozil be formulated as an orally disintegrating tablet?

Yes. An orally disintegrating tablet is technically feasible, but the 600 mg dose creates tablet-size, taste, friability, and dose-uniformity challenges. Taste masking and rapid dissolution would be central development requirements.

Which excipient is most important for gemfibrozil dissolution?

No single excipient is universally determinative. Wetting agents, particle-size control, superdisintegrants, and granulation conditions usually have greater impact than the choice of diluent alone.

Is a gemfibrozil fixed-dose combination commercially attractive?

The opportunity is limited by gemfibrozil’s interaction profile, particularly with simvastatin and other medicines affected by CYP2C8 inhibition. Any combination would require a strong clinical rationale and interaction-specific development.

Can a new gemfibrozil formulation receive five years of new-drug exclusivity?

A reformulated product would not automatically receive new chemical entity exclusivity because gemfibrozil is an established active ingredient. Other exclusivity provisions may depend on the specific regulatory pathway and clinical development package.

Would micronized gemfibrozil support a strong patent?

Micronization alone may be vulnerable to obviousness and prior-art challenges. A stronger patent position would require a defined particle-size distribution linked to unexpected dissolution, exposure, stability, or manufacturing results.

References

1. U.S. Food and Drug Administration. (2023). Gemfibrozil tablets, USP: Prescribing information. DailyMed.
2. National Center for Biotechnology Information. (2024). PubChem compound summary for gemfibrozil. PubChem.
3. U.S. National Library of Medicine. (2024). Gemfibrozil tablet: Inactive ingredients and product labeling. DailyMed.
4. U.S. Food and Drug Administration. (2024). Inactive Ingredient Database. FDA.
5. U.S. Food and Drug Administration. (2023). Approved drug products with therapeutic equivalence evaluations. FDA.